Trials / Completed
CompletedNCT04149587
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
A Canadian Phase IV, Multicenter, Single-Arm Study To Evaluate the Effectiveness of Treatment With Brodalumab (SILIQ) in Psoriasis Patients With Inadequate Response to Their Current Biologic Agent Regimen
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 252 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, prospective, observational, single-arm, 26-week study will evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis with inadequate response to their current biologic agent regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brodalumab | Brodalumab will be administered per dose and schedule specified in the arm. |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2022-03-30
- Completion
- 2022-03-30
- First posted
- 2019-11-04
- Last updated
- 2022-07-15
Locations
11 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04149587. Inclusion in this directory is not an endorsement.